Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brii BiosciencesFRA:7SS +0.51%33 EV-to-EBIT is 6.62 as of Jul. 27, 2026, which is 8% below its 10-year median of 7.22. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 378 Biotechnology companies, Brii Biosciences ranks better than 62.17% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Brii Biosciences's Enterprise Value for the quarter that ended in Dec. 2025 was €-138.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-26.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences EV-to-EBIT Related Terms
Brii Biosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7SS vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Brii Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's EV-to-EBIT falls into.
Brii Biosciences's current Enterprise Value is €-176.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-26.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences (FRA:7SS) has a EV-to-EBIT of 6.62 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Brii Biosciences and its competitors. This is near median its historical median of 7.22. According to the industry distribution chart, Brii Biosciences ranks #143 out of 378 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Brii Biosciences' EV-to-EBIT too high?
Brii Biosciences' current EV-to-EBIT of 6.62 is near median its 10-year median of 7.22. The Biotechnology industry median EV-to-EBIT is 12.78. Brii Biosciences' value of 6.62 is 48.2% below this industry median. Based on the distribution chart, Brii Biosciences ranks #143 out of 378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #143 out of 378 companies for EV-to-EBIT. This puts Brii Biosciences in the upper half of its industry. The industry median EV-to-EBIT is 12.78. Brii Biosciences' value of 6.62 is 48.2% below this benchmark. While the company's 10-year median is 7.22 vs. the industry median of 12.78, Brii Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brii Biosciences's current EV-to-EBIT of 6.62 is 48.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Brii Biosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brii Biosciences's current EV-to-EBIT is 6.62, which is near median its own 10-year median of 7.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current EV-to-EBIT of 6.62. The current EV-to-EBIT is 6.62, which is near median its 10-year median of 7.22 and 48.2% below the Biotechnology industry median of 12.78. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current EV-to-EBIT is 6.62 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
